HealthEquity, Inc. - Common Stock (HQY)
113.06
+9.30 (8.96%)
NASDAQ · Last Trade: Jun 4th, 10:53 PM EDT
Detailed Quote
Previous Close | 103.76 |
---|---|
Open | 112.08 |
Bid | 112.65 |
Ask | 113.95 |
Day's Range | 107.76 - 116.00 |
52 Week Range | 65.01 - 115.59 |
Volume | 2,712,418 |
Market Cap | 9.43B |
PE Ratio (TTM) | 103.72 |
EPS (TTM) | 1.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 954,701 |
Chart
About HealthEquity, Inc. - Common Stock (HQY)
Healthequity is a leading provider of health savings accounts and other consumer-directed benefits, facilitating individuals and employers in managing healthcare expenses. The company offers a robust platform that integrates various services, including healthcare spending accounts, wellness services, and insurance products, aimed at empowering consumers to make informed healthcare decisions. By promoting cost-saving strategies and enhancing access to critical healthcare resources, Healthequity plays a vital role in the healthcare ecosystem, making it easier for users to navigate their financial responsibilities associated with medical care. Read More
News & Press Releases

Via Benzinga · June 4, 2025

Via Benzinga · June 4, 2025

Via Benzinga · June 4, 2025

Via Benzinga · June 4, 2025

Here's a look at HealthEquity's first-quarter earnings report.
Via Benzinga · June 3, 2025

HEALTHEQUITY INC (NASDAQ:HQY) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for investors seeking growth opportunities.
Via Chartmill · May 28, 2025
Via Benzinga · May 23, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 19, 2025
Via Benzinga · May 13, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 9, 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 5, 2025
Via Benzinga · May 1, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 29, 2025
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 27, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 25, 2025
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 21, 2025
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 21, 2025
Based on fundamental and technical analysis of NASDAQ:HQY we ask: Why HEALTHEQUITY INC (NASDAQ:HQY) Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill · April 18, 2025
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 17, 2025